OncoMatch/Clinical Trials/NCT07129252
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Is NCT07129252 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies CRN09682 for sst2-positive neuroendocrine neoplasms.
Treatment: CRN09682 — This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Neuroendocrine Tumor
Biomarker criteria
Required: SSTR2 expression confirmed by SSR imaging
tumor that expresses SSR confirmed by SSR imaging
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: peptide receptor radionuclide therapy
tumor progression while undergoing a course of PRRT or within 6 months of completing PRRT
Cannot have received: MMAE-containing therapy (MMAE)
prior treatment with MMAE
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Crinetics Study Site · Duarte, California
- Crinetics Study Site · Newport Beach, California
- Crinetics Study Site · Orange, California
- Crinetics Study Site · San Francisco, California
- Crinetics Study Site · Denver, Colorado
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07129252 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior peptide receptor radionuclide therapy, MMAE-containing therapy disqualifies patients from enrollment.
Does this trial require SSTR2?
Yes, SSTR2 expression confirmed by SSR imaging is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify